Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of VAL-083 Treatment for MGMT Unmethylated Bevacizumab-naïve Glioblastoma in the Adjuvant or Recurrent Setting

NCT02717962 is registered in ClinicalTrials.gov with Kintara Therapeutics, Inc. as lead sponsor.

NCT NCT02717962
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02717962 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of VAL-083 Treatment for MGMT Unmethylated Bevacizumab-naïve Glioblastoma in the Adjuvant or Recurrent Setting
Lead sponsor
Kintara Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
January 20, 2017
Completion date
December 30, 2024
Enrollment
118 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain cancer, gbm, glioblastoma, glioblastoma multiforme, glioma